Small, stable and robust, VHH offer an attractive construct for incorporation as targeting agents in cell therapies.
VHH can also be easily engineered with carefully designed affinities, valencies and specificities to meet a variety of therapeutic needs, enabling refined cell targeting and modes of action while also minimising off-target toxicity.
VHH in Cell Therapy
VHH in CAR-T Resources
Clinical landscape and applications of single domain VHH antibodies for optimisation of next generation T-cell immunodirection therapies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities.
Using Llamda-VHH to optimize T-cell mediated immunotherapies
In this webcast, speakers will introduce the unique benefits of the VHH antibodies generated from the hLlamdA™ synthetic library and summarize how single domain VHH antibodies can be engineered to tune their binding selectivity and specificity for antigen targeting and be applied to optimize the next generation of these important new therapeutic modalities.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.